Latest Breaking News On - Pressure enabled drug delivery - Page 4 : comparemela.com

TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results

TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Exchange commissionTrisalus life sciencesSee the company quarterly report on formSalus life sciencesUnaudited fourth quarterFull yearInfusion systemPressure enabled drug deliveryPancreatic retrograde venous infusion systemPressure enabled regional immuno oncologyPrivate securities litigation reform actQuarterly reportInvestor inquiriesTrisalus life

TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors

DENVER (BUSINESS WIRE) Feb 29, 2024

United statesMary szelaTrinav smartvalveStevenc katzCenters for medicareCurrent medical researchTrisalus life sciencesSalus life sciencesChief executive officerHealthcare common procedure coding systemChief medical officerTrinav infusionPressure enabled drug deliveryTranscatheter arterial chemoembolizationTranscatheter arterial radioembolizationInfusion system

Baltimore s Haystack Oncology, TriSalus Life Sciences to develop liver cancer treatment

Baltimore s Haystack Oncology, TriSalus Life Sciences to develop liver cancer treatment
thedailyrecord.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thedailyrecord.com Daily Mail and Mail on Sunday newspapers.

Quest diagnosticsTrisalus life sciencesHaystack oncologyPressure enabled drug delivery

Haystack Oncology, developer of Haystack MRD™, and TriSalus Life Sciences collaborate in connection with the clinical development of TriSalus TLR9 agonist in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma

BALTIMORE, Jan. 22, 2024 /PRNewswire/ Haystack Oncology, a Quest Diagnostics company and developer of best-in-class personalized MRD technology , has entered a research collaboration with.

Eteläuomen läiUnited statesDan edelsteinSteven katzResearch useTrisalus life sciencesQuest diagnosticsJohns hopkins school of medicinePressure enabled drug deliveryVice presidentGeneral managerChief medical officerTrisalus lifeJohns hopkins schoolResearch use only

SD-101 With Immune Checkpoint Inhibition Generates Positive Results in Uveal Melanoma Liver Metastasis

Treatment with SD-101 distributed via pressure-enabled drug delivery with immune checkpoint inhibition was tolerated and resulted in the depletion of Tregs, M-MDSCs, and M2 macrophages in liver metastases in patients with uveal melanoma.

San diegoUnited statesSapna patelMelanoma fellowship programDepartment of melanoma medical oncologyUniversity of texas md anderson cancer centerUveal melanoma programMelanoma medical oncologyCancer centerEsd 101M mdscsPressure enabled drug delivery2023 sitc annual meetingPhase 1 perio 01 trial